JP2002503227A - Vcam−1発現を阻害する化合物および方法 - Google Patents
Vcam−1発現を阻害する化合物および方法Info
- Publication number
- JP2002503227A JP2002503227A JP54950298A JP54950298A JP2002503227A JP 2002503227 A JP2002503227 A JP 2002503227A JP 54950298 A JP54950298 A JP 54950298A JP 54950298 A JP54950298 A JP 54950298A JP 2002503227 A JP2002503227 A JP 2002503227A
- Authority
- JP
- Japan
- Prior art keywords
- butyl
- substituted
- alkyl
- spacer
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 title claims abstract description 49
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 title claims abstract description 49
- 230000014509 gene expression Effects 0.000 title claims abstract description 32
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 title claims description 175
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 12
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 12
- -1 nitro, amino Chemical group 0.000 claims description 1279
- 125000000217 alkyl group Chemical group 0.000 claims description 234
- 125000006850 spacer group Chemical group 0.000 claims description 126
- 125000001072 heteroaryl group Chemical group 0.000 claims description 123
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 112
- 125000003118 aryl group Chemical group 0.000 claims description 85
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 239000001257 hydrogen Substances 0.000 claims description 68
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 62
- 125000003342 alkenyl group Chemical group 0.000 claims description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- 229910052757 nitrogen Inorganic materials 0.000 claims description 58
- 125000000304 alkynyl group Chemical group 0.000 claims description 55
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 37
- 125000003107 substituted aryl group Chemical group 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- 125000004423 acyloxy group Chemical group 0.000 claims description 30
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 30
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 29
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 22
- 125000000837 carbohydrate group Chemical group 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 21
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 21
- 201000001320 Atherosclerosis Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 15
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 125000001188 haloalkyl group Chemical group 0.000 claims description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000037803 restenosis Diseases 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 229930064664 L-arginine Natural products 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- SKCKOFZKJLZSFA-UHFFFAOYSA-N 1-deoxy-D-glucitol Chemical compound CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 claims description 5
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 5
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
- 200000000007 Arterial disease Diseases 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 208000028922 artery disease Diseases 0.000 claims description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000004193 piperazinyl group Chemical group 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims description 4
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 241001024304 Mino Species 0.000 claims description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 claims description 4
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 229940127218 antiplatelet drug Drugs 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical group CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims description 3
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229960004676 antithrombotic agent Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002411 adverse Effects 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 6
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 claims 3
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 claims 2
- 102000008068 Tensins Human genes 0.000 claims 2
- 108010088950 Tensins Proteins 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000002327 cardiovascular agent Substances 0.000 claims 2
- 229940125692 cardiovascular agent Drugs 0.000 claims 2
- 231100000989 no adverse effect Toxicity 0.000 claims 2
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 241000534944 Thia Species 0.000 claims 1
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 136
- 230000001404 mediated effect Effects 0.000 abstract description 11
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 165
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 158
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 147
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 139
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 130
- 238000006243 chemical reaction Methods 0.000 description 95
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 91
- 239000000243 solution Substances 0.000 description 76
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 73
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 72
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 238000005160 1H NMR spectroscopy Methods 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 239000000047 product Substances 0.000 description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 48
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 43
- 235000019341 magnesium sulphate Nutrition 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 42
- 229960003912 probucol Drugs 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 108010007622 LDL Lipoproteins Proteins 0.000 description 37
- 102000007330 LDL Lipoproteins Human genes 0.000 description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 32
- 239000010410 layer Substances 0.000 description 30
- 239000007787 solid Substances 0.000 description 29
- 239000002253 acid Substances 0.000 description 28
- 239000003480 eluent Substances 0.000 description 27
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 27
- 239000000377 silicon dioxide Substances 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 23
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- 239000012267 brine Substances 0.000 description 22
- 239000012044 organic layer Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 239000003921 oil Substances 0.000 description 21
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 239000012312 sodium hydride Substances 0.000 description 19
- 229910000104 sodium hydride Inorganic materials 0.000 description 19
- 238000003756 stirring Methods 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 18
- 150000002632 lipids Chemical group 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000002390 rotary evaporation Methods 0.000 description 17
- 239000002480 mineral oil Substances 0.000 description 16
- 235000010446 mineral oil Nutrition 0.000 description 16
- 229910019142 PO4 Inorganic materials 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000010452 phosphate Substances 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 235000011121 sodium hydroxide Nutrition 0.000 description 14
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- 238000004809 thin layer chromatography Methods 0.000 description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 10
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 9
- NFVMNXZFSKGLDR-UHFFFAOYSA-N 2,6-ditert-butyl-4-sulfanylphenol Chemical compound CC(C)(C)C1=CC(S)=CC(C(C)(C)C)=C1O NFVMNXZFSKGLDR-UHFFFAOYSA-N 0.000 description 8
- WEPUYTBETYHQKS-UHFFFAOYSA-N 2,6-ditert-butylbenzenethiol Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=C1S WEPUYTBETYHQKS-UHFFFAOYSA-N 0.000 description 8
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 102000015779 HDL Lipoproteins Human genes 0.000 description 8
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 102000018616 Apolipoproteins B Human genes 0.000 description 6
- 108010027006 Apolipoproteins B Proteins 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010024212 E-Selectin Proteins 0.000 description 5
- 102100023471 E-selectin Human genes 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 229940045348 brown mixture Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 238000005502 peroxidation Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012746 preparative thin layer chromatography Methods 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000002274 desiccant Substances 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- 125000001033 ether group Chemical group 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 210000000497 foam cell Anatomy 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011698 potassium fluoride Substances 0.000 description 4
- 235000003270 potassium fluoride Nutrition 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- DKCPKDPYUFEZCP-UHFFFAOYSA-N 2,6-di-tert-butylphenol Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=C1O DKCPKDPYUFEZCP-UHFFFAOYSA-N 0.000 description 3
- UXFWTIGUWHJKDD-UHFFFAOYSA-N 2-(4-bromobutyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCBr)C(=O)C2=C1 UXFWTIGUWHJKDD-UHFFFAOYSA-N 0.000 description 3
- VQDJODAWOFNASI-UHFFFAOYSA-N 2-propylpropanedioic acid Chemical compound CCCC(C(O)=O)C(O)=O VQDJODAWOFNASI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 108010004103 Chylomicrons Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical group Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 229910052792 caesium Inorganic materials 0.000 description 3
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 125000000466 oxiranyl group Chemical class 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 2
- BKHZLTKQOBJPLB-UHFFFAOYSA-N 1,3-thiazole-4,5-dicarbaldehyde Chemical compound O=CC=1N=CSC=1C=O BKHZLTKQOBJPLB-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- BFWYTORDSFIVKP-USWFWKISSA-N 15-HPETE Chemical compound CCCCCC(OO)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O BFWYTORDSFIVKP-USWFWKISSA-N 0.000 description 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 2
- CYZWRSGPZFHCEN-UHFFFAOYSA-N 2,6-ditert-butylphenol 2,6-dimethylphenol Chemical compound CC1=CC=CC(C)=C1O.CC(C)(C)C1=CC=CC(C(C)(C)C)=C1O CYZWRSGPZFHCEN-UHFFFAOYSA-N 0.000 description 2
- WQINSVOOIJDOLJ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetic acid Chemical compound C1=CC=C2C(=O)N(CC(=O)O)C(=O)C2=C1 WQINSVOOIJDOLJ-UHFFFAOYSA-N 0.000 description 2
- MCRZWYDXIGCFKO-UHFFFAOYSA-N 2-butylpropanedioic acid Chemical compound CCCCC(C(O)=O)C(O)=O MCRZWYDXIGCFKO-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- WJQOZHYUIDYNHM-UHFFFAOYSA-N 2-tert-Butylphenol Chemical compound CC(C)(C)C1=CC=CC=C1O WJQOZHYUIDYNHM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 102000003790 Thrombin receptors Human genes 0.000 description 2
- 108090000166 Thrombin receptors Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001347 alkyl bromides Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical group O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- VLSJPRHEVMZIII-UHFFFAOYSA-N diethoxyborinic acid Chemical compound CCOB(O)OCC VLSJPRHEVMZIII-UHFFFAOYSA-N 0.000 description 2
- WSEQLMQNPBNMSL-FJXQXJEOSA-N diethyl (2s)-2-aminopentanedioate;hydron;chloride Chemical compound Cl.CCOC(=O)CC[C@H](N)C(=O)OCC WSEQLMQNPBNMSL-FJXQXJEOSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 150000002432 hydroperoxides Chemical class 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Substances SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- MYZCBEQJKJGPHH-RRFVWWEKSA-N (2R,3R,4S,5S,6R)-6-[[2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenoxy]methyl]oxane-2,3,4,5-tetrol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC(C)(C)SC=2C=C(C(OC[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](O)O3)O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 MYZCBEQJKJGPHH-RRFVWWEKSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- QDSPKVAVEIXQJG-ICHFNJPQSA-N (3R,4S,5R,6S)-6-(1-hydroxybut-1-enyl)oxane-2,3,4,5-tetrol Chemical compound CCC=C(O)[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O QDSPKVAVEIXQJG-ICHFNJPQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- YAXKTBLXMTYWDQ-UHFFFAOYSA-N 1,2,3-butanetriol Chemical compound CC(O)C(O)CO YAXKTBLXMTYWDQ-UHFFFAOYSA-N 0.000 description 1
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- SRYFPKKLUIWUGW-UHFFFAOYSA-N 1-(2-iodoethyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CCI)C=C1 SRYFPKKLUIWUGW-UHFFFAOYSA-N 0.000 description 1
- IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- DARDYTBLZQDXBK-UHFFFAOYSA-N 1-(chloromethyl)-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CCl)C([N+]([O-])=O)=C1 DARDYTBLZQDXBK-UHFFFAOYSA-N 0.000 description 1
- APGGSERFJKEWFG-UHFFFAOYSA-N 1-(chloromethyl)-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(CCl)=C1 APGGSERFJKEWFG-UHFFFAOYSA-N 0.000 description 1
- INKNHBKFSPIMKS-UHFFFAOYSA-N 1-(iodomethyl)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(CI)C=C1 INKNHBKFSPIMKS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- BPMXOBNFOWJWKL-UHFFFAOYSA-N 2,3,4-triphenylphosphinine Chemical compound C1=CC=CC=C1C1=CC=PC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BPMXOBNFOWJWKL-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- OOASKUJFEVSVNH-UHFFFAOYSA-N 2-butyl-4-sulfanylphenol Chemical compound CCCCC1=CC(S)=CC=C1O OOASKUJFEVSVNH-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- KIHAGWUUUHJRMS-JOCHJYFZSA-N 2-octadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CO)COP(O)(=O)OCCN KIHAGWUUUHJRMS-JOCHJYFZSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- QJVYRYDARHKQAF-UHFFFAOYSA-N 3,3-dimethyl-2-methylidenebutanoic acid Chemical compound CC(C)(C)C(=C)C(O)=O QJVYRYDARHKQAF-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- WKCYFSZDBICRKL-UHFFFAOYSA-N 3-(diethylamino)propan-1-ol Chemical compound CCN(CC)CCCO WKCYFSZDBICRKL-UHFFFAOYSA-N 0.000 description 1
- JSAYPSXBCDUDKB-UHFFFAOYSA-N 3-bromopropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCBr JSAYPSXBCDUDKB-UHFFFAOYSA-N 0.000 description 1
- LJQNMDZRCXJETK-UHFFFAOYSA-N 3-chloro-n,n-dimethylpropan-1-amine;hydron;chloride Chemical compound Cl.CN(C)CCCCl LJQNMDZRCXJETK-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- OFKHGGBURKUCOM-UHFFFAOYSA-N 4-(tetrazol-1-yl)butanoic acid Chemical compound OC(=O)CCCN1C=NN=N1 OFKHGGBURKUCOM-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- NDWUBGAGUCISDV-UHFFFAOYSA-N 4-hydroxybutyl prop-2-enoate Chemical compound OCCCCOC(=O)C=C NDWUBGAGUCISDV-UHFFFAOYSA-N 0.000 description 1
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 1
- FHEDUEMPPQAEEW-UHFFFAOYSA-N 4-nitrofuran-2-carbonyl chloride Chemical compound [O-][N+](=O)C1=COC(C(Cl)=O)=C1 FHEDUEMPPQAEEW-UHFFFAOYSA-N 0.000 description 1
- GBRSPKXOFRTAHS-UHFFFAOYSA-N 5-(4-nitrophenyl)-1,2-oxazole-3-carboxylic acid Chemical compound O1N=C(C(=O)O)C=C1C1=CC=C([N+]([O-])=O)C=C1 GBRSPKXOFRTAHS-UHFFFAOYSA-N 0.000 description 1
- ZCYVIAZIVJNAMO-UHFFFAOYSA-N 5-chloropentyl acetate Chemical compound CC(=O)OCCCCCCl ZCYVIAZIVJNAMO-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- KMWYETDRINUHMV-UHFFFAOYSA-N C(C)(C)(C)C1=C(C(=CC=C1)C(C)(C)C)O.NCCCCOC1=C(C=CC=C1C)C Chemical compound C(C)(C)(C)C1=C(C(=CC=C1)C(C)(C)C)O.NCCCCOC1=C(C=CC=C1C)C KMWYETDRINUHMV-UHFFFAOYSA-N 0.000 description 1
- JAYSXLQXCAZQED-UHFFFAOYSA-N CCI.C(C)(=O)O Chemical compound CCI.C(C)(=O)O JAYSXLQXCAZQED-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- SBUKLPSBNFWJCU-UHFFFAOYSA-N ClIBr Chemical compound ClIBr SBUKLPSBNFWJCU-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 101000936738 Coturnix japonica Astacin-like metalloendopeptidase Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZFIVKAOQEXOYFY-UHFFFAOYSA-N Diepoxybutane Chemical compound C1OC1C1OC1 ZFIVKAOQEXOYFY-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101100370100 Mus musculus Tor3a gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000794562 Naegleria gruberi Calmodulin, flagellar Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- UNGZTYDSSPJLGS-UHFFFAOYSA-N OC1=CC=C([SiH3])C=C1 Chemical class OC1=CC=C([SiH3])C=C1 UNGZTYDSSPJLGS-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241001165766 Tetraoninae Species 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UZSZMXBSNKGZHA-UHFFFAOYSA-N [4-[2-[4-(pyridine-3-carbonyloxy)phenyl]sulfanylpropan-2-ylsulfanyl]phenyl] pyridine-3-carboxylate Chemical class C(C1=CN=CC=C1)(=O)OC1=CC=C(C=C1)SC(C)(C)SC1=CC=C(C=C1)OC(C1=CN=CC=C1)=O UZSZMXBSNKGZHA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000008369 airway response Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N alpha-D-galactose Natural products OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000006427 angiogenic response Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 208000037741 atherosclerosis susceptibility Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OLIBHZVRLPRRHI-UHFFFAOYSA-N benzoic acid;carbonic acid Chemical class OC(O)=O.OC(=O)C1=CC=CC=C1 OLIBHZVRLPRRHI-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CRWKHBIQAIGSSV-UHFFFAOYSA-N boric acid;methylsulfanylmethane Chemical compound CSC.OB(O)O CRWKHBIQAIGSSV-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 230000003312 cholesterol blood level Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000026721 endothelial cell chemotaxis Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 229940093470 ethylene Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001269 glycine hydrochloride Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 229940126707 lipid peroxidation inhibitor Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VXJIMUZIBHBWBV-UHFFFAOYSA-M lithium;chloride;hydrate Chemical compound [Li+].O.[Cl-] VXJIMUZIBHBWBV-UHFFFAOYSA-M 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- IBUFLVFZAOMSEY-UHFFFAOYSA-N methanimine hydrate Chemical compound O[H].[H]C=N IBUFLVFZAOMSEY-UHFFFAOYSA-N 0.000 description 1
- SPAKMVQVTSVXES-UHFFFAOYSA-N methanol;oxolane;hydrate Chemical compound O.OC.C1CCOC1 SPAKMVQVTSVXES-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- PWXMEBZOKUPCST-UHFFFAOYSA-N methyl 5-(chloromethyl)furan-2-carboxylate Chemical compound COC(=O)C1=CC=C(CCl)O1 PWXMEBZOKUPCST-UHFFFAOYSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012476 oxidizable substance Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008379 phenol ethers Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N phthalic acid di-n-butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- MJIBOYFUEIDNPI-HBNMXAOGSA-L zinc 5-[2,3-dihydroxy-5-[(2R,3R,4S,5R,6S)-4,5,6-tris[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]-2-[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxymethyl]oxan-3-yl]oxycarbonylphenoxy]carbonyl-3-hydroxybenzene-1,2-diolate Chemical compound [Zn++].Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c([O-])c([O-])c2)c1 MJIBOYFUEIDNPI-HBNMXAOGSA-L 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/21—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/66—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
- C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式(I)の化合物であって、 XがO,S,SO,SO2、CH2、またはNHであり; スペーサーが−(CH2)n−、−(CH2)n−CO−、−(CH2)n−N−、− (CH2)n−O−、−(CH2)n−S−、−(CH2O)−、−(OCH2)−、 −(SH2)−、−(CH2S−)、−(アリール−O)−、−(O−アリール) −、(アルキル−O)−、−(O−アルキル)−の基から選択された基であり; nが0、1、2、3、4、5、6、7、8、9、または10であり; Yが置換または非置換のアリール、置換または非置換のヘテロアリール、置換 または非置換のアルキル、置換または非置換のアルコキシ、置換または非置換の アルコキシアルキル、置換または非置換のアルキルチオ、置換または非置換のア ルキルチ オアルキル、置換または非置換のアルキルスルフィニル、置換または非置換のア ルキルスルフィニルアルキル、置換または非置換のアルキルスルフォニル、置換 または非置換のアルキルスルフォニルアルキル、NH2、NHR、NR2、SO2 −OH、OC(O)R、C(O)OH、C(O)OR、C(O)NH2、C(O )NHR、C(O)NR2、SO2NH2、SO2NHR、SO2NR2であり; Rがアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、置 換アルキニル、アリール、置換アリール、アルキル−COOH、アルキル−CO Oアルキル、アルキル−COOアリール、ヘテロアリール、置換ヘテロアリール であり、または窒素原子に結合しているとき、隣接した2つのR基が一緒に5か ら7員環を形成することができ; R1およびR2はそれぞれ独立した置換されたものでもよい直鎖、分枝、または 環状アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール 、アルカリル、またはアラルキルであり、R1またはR2基の置換基は水素、ハロ ゲン、アルキル、ニトロ、アミノ、アルキルアミノ、ジアルキルアミノ、アシル 、およびアシロキシからなる群から選択され; R3およびR4はそれぞれ独立に、分子の望ましい特性に他の悪影響を及ぼさな い、H、ハロゲンまたはR1を含む任意の基であり; 化合物または薬学的に容認されたその塩。 2.XがS、SO、またはSO2;スペーサーが−(CH2)n−または−(CH2 )n−CO−;nが0〜10;Yがアリール、置換アリール、ヘテロアリール、 置換ヘテロアリール、NH2、NHR、アルキル、置換アルキル、アシルオキシ および置換アシルオキシ;Rがアルキル、アルケニル、アルキニル、アリール、 アルキル−COOH、アルキル−COOアルキル、アルキル−COOアリール、 ヘテロアリール、またはニトロ置換ヘテロアリール、あるいは窒素原子に結合し た場合、隣接したR基が共に5から7員環を形成することができ;R1およびR2 は独立に直鎖、分枝または環状C1-5アルキルであり;R3およびR4は独立にH である、 化合物または薬剤として許容されるその塩。請求の範囲第1項に記載の化合物 。 3.式(I)の化合物からなる群から選択された請求の範囲第2項に記載の化合 物または薬剤として許容されるその塩であっ て、 X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−カルボキシメチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−カルボキシエチル X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=3,5−ジ−t−ブチル−4−カルボキシプロパノイルオキシ ; X=S;R1=t−ブチル、R2=t−ブチル;R3=H;R4=H;スペーサー= −CH2−;Y=4−カルボキシフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=1−アセチロキシ−1−メチルエチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4 =H;スペーサー=−CH2−;Y=3−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2,4−ジニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−トリフルオロメチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−カルボキシフラニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−(N,N−ジメチル)スルフォンアミドフェニル; X=SO;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー =−CH2−;Y=4−ニトロフェニル; X=SO2;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサ ー=−CH2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=アセチルオキシフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−メチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−フルオロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=エチルスルホン酸; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−ジメチルアミノメチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)3−;Y=ジメチルアミノ; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)5−;Y=アセチルオキシ;および X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−(2−ヒドロキシ)エチルフェニル; である化合物または塩。 4.請求の範囲第1項、2または3のいずれかに記載の化合物または薬剤として 許容される塩の有効量および薬剤として許容される担体を含む、VCAM−1の 発現によりもたらされる疾患を治療するための薬剤組成物。 5.VCAM−1の発現によりもたらされる障害を治療する方法であって、請求 の範囲第1項、2、または3のいずれか一項に記載の式(I)の化合物または薬 剤として許容されるその塩の有効量を、随意に薬剤として許容される担体に含め 、患者に投与することを含む治療方法。 6.障害が心臓血管性障害である請求の範囲第5項に記載の方法。 7.心臓血管性障害がアテローム性動脈硬化、血管形成術後再狭窄、冠状動脈疾 患、アンギナ、または小動脈疾患からなる群から選択される請求の範囲第6項に 記載の方法。 8.障害が炎症性疾患である請求の範囲第5項に記載の方法。 9.炎症性疾患がリュウマチ性関節炎、変形性関節炎、喘息、皮膚炎、多発性硬 化症、および乾癬からなる群から選択される請求の範囲第8項に記載の方法。 10.式(II)の化合物であって、 Ra、Rb、RcおよびRdはそれぞれ独立に、分子の望ましい特性に悪影響を及 ぼさない水素、置換されたものでもよい直鎖、分枝または環状アルキル、アリー ル、置換アリール、ヘテロアリール、置換ヘテロアリール、アルカリル、置換ア ルカリル、アラルキルまたは置換アラルキルを含む任意の基であり; Ra、Rb、RcおよびRd基の置換は水素、ハロゲン、アルキル、ニトロ、アミノ 、ハロアルキル、アルキルアミノ、ジアルキルアミノ、アシルおよびアシルオキ シからなる基から選択される; Zは水素、アルキル、置換アルキル、アルケニル、置換アルケニル、アルキニ ル、置換アルキニル、アリール、アラルキル、アルカリル、ヘテロアリール、ヘ テロアラルキル、炭水化物基、−(CH2)−Re、−C(O)−Rg、および− C(O)−(CH2)n−Rhからなる群から選択され、(a)Ra、Rb、Rcおよ びRdがそれぞれt−ブチルの場合、Zは水素ではありえず、(b)Ra、Rb、 RcおよびRdがそれぞれt−ブチルの場合、Zはコハク酸残基でありえず; Reはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルコキシ、 アルコキシアルキル、置換アルコキシアルキル、NH2、NHR、NR2、モノ− またはポリヒドロキシ置換アルキル、アリール、置換アリール、ヘテロアリール 、置換ヘテロアリール、アシルオキシ、置換アシルオキシ、COOH、COOR 、−CH(OH)Rk、ヒドロキシ、C(O)NH2、C(O)NHR、C(O) NR2からなる基から選択され; Rgはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルキルオキシ、アルコキシアルキル、置換 アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒドロキシ置換 アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリールから なる基から選択され; Rhはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルキルオキシ、アルコキシアルキル、置換 アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒドロキシ置換 アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、ア シルオキシ、置換アシルオキシ、COOH、COOR、−CH(OH)Rk、ヒ ドロキシ、O−リン酸、C(O)NH2、 C(O)NHR、C(O)NR2からなる群から選択され; または、別の実施形態では、Re、RgおよびRhはそれぞれ独立に、C(O) −スペーサー−SO3H(スペーサーは上記で定義したもの、C(O)−スペー サー−SO3M(Mはナトリウムなど薬剤として許容される塩を形成するために 使用される金属)、C(O)−スペーサー−PO3H2、C(O)−スペーサー− PO3M2、C(O)−スペーサー−PO3HM、C(O)ースペーサー−PO4H 、C(O)−スペーサー−PO4M、SO3M、−PO3H2、−PO3M2、−PO3 HM、環状リン酸、ポリヒドロキシアルキル、炭水化物基、C(O)−スペー サー−[O(C1-3アルキル)p]nを含むがそれだけに限らない、化合物の水溶 性を改善する置換基とすることができ、nは上記で定義されたものであり、pは 1、2、または3、−[O(C1-3アルキル)p]n、カルボキシ低級アルキル、 低級アルキルカルボニル低級アルキル、N,N−ジアルキルアミノ低級アルキル 、ピリジル低級アルキル、イミダゾリル低級アルキル、モルフォリニル低級アル キル、ピロリジニル低級アルキル、チアゾリニル低級アルキル、ピペリジニル低 級アルキル、モルフォリニル低ヒドロキシアルキル、N−ピリル、ピペラジニル 低 級アルキル、N−アルキルピペラジニル低級アルキル、トリアゾリル低級アルキ ル、テトラゾリル低級アルキル、テトラゾリルアミノ低級アルキル、またはチア ゾリル低級アルキルである、化合物または薬剤として許容されるその塩。 11.Ra、Rb、RcおよびRdがそれぞれ独立に水素または直鎖、分枝または環 状C1-10アルキルであり;Zは水素、アルキル、置換アルキル、アルケニル、置 換アルケニル、アルキニル、置換アルキニル、炭水化物基、−(CH2)−Re− 、−C(O)−Rg、−C(O)−(CH2)n−Rhおよび薬剤として許容される その塩からなる群から選択され、(a)Ra、Rb、RcおよびRdがそれぞれt− ブチルの場合、Zは水素ではありえず、(b)Ra、Rb、RcおよびRdそれぞれ がt−ブチルの場合、Zはコハク酸残基でありえない、請求の範囲第10項に記 載の化合物。 12.式(II)の化合物からなる群から選択された請求の範囲第11項の化合 物または薬剤として許容されるその塩であって、 Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−ニトロフェニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(CH2)2−COOH; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(5−ニトロフラン−2−イル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−カルボキシプロピル; Ra=1−メチルエチル、Rb=t−ブチル、Rc=t−メチル、およびRd=メチ ル;Z=4−アミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−アミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシプロパノイル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;z=t−ブチルカルボニルオキシメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=H、およびRd=H;Z=4−アミノ ブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=H、およびRd=H;Z=3−カルボ キシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=カルボキシメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−(CONH2)エタノイル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アミノメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(2−カルボキシエチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(2−メトキシカルボニルエチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アミノメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−カルボキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−カルボキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アンモニウムメチル(クロリド); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−2−オキシラニル−エチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシメチルオキシラニ−2−イルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−(2−ヒドロキシ−2−オキシラニル)エトキシキシラン−2−イル メチル;Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t −ブチル;Z=オキシラニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−カルボキシメチルアミノプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3,4−トリヒドロキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−エトキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3−ジヒドロキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=エチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−エトキシカルボニルエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−N,N−ジメチルアミノフェネチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル(L−アルギニンエステル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−メトキシカルボニルプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−カルボキシエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=ガラクトピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−(N−N−ジエチルアミノ)プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−エトキシカルボニルエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=カルボキシメチルアミノカルボニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=1,3−ジカルボキシプロピルアミノカルボニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−(1,3−ジエトキシカルボニル)プロピルアミノ プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=2,3−ジヒドロキシ−4−カルボキシメチルアミノ ブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−(5−アミノ−5−カルボキシ)プロピルアミノプ ロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−エチルカルボニルオキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−ヒドロキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=グルコピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−テトラゾリルプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシプロペニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CONH−(CH2)CH(NH2)COOH; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=CH2CONHCH(COOet)CH2CH2(COOet ); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=グルコピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3,4,5,6−ペンタヒドロキシヘキサン; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−(2−ヒドロキシフェニルオキシホスホキシ)プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2,2−ジメチル−3−ヒドロキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−アセトキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−アセトキシ−3−ヒドロキシプロピル;かつ Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CH(OH)CH2NH(2,3,4,5,6−ペンタヒドロキシヘ キサンである; 化合物または塩。 13.請求の範囲第10項、第11項または第12項のいずれか一項に記載の化 合物または薬剤として許容されるその塩の有効量および薬剤として許容される担 体を含む、VCAM−1の発現によりもたらされる疾患を治療するための薬剤組 成物。 14.VCAM−1の発現によりもたらされる障害を治療する方法であって、請 求の範囲第10項、第11項、または第12項のいずれか一項に記載の化合物ま たは薬剤として許容されるその塩の有効量を、随意に薬剤として許容される担体 に含めて、患者に投与することを含む方法。 15.障害が心臓血管性障害である、請求の範囲第14項に記載の方法。 16.心臓血管性障害がアテローム性動脈硬化、血管形成術後再狭窄、冠状動脈 疾患、アンギナ、または小動脈疾患からなる群から選択される、請求の範囲第1 5項に記載の方法。 17.障害が炎症性疾患である、請求の範囲第14項に記載の 方法。 18.炎症性疾患がリュウマチ性関節炎、変形性関節炎、喘息、皮膚炎、多発性 硬化症、および乾癬からなる群から選択される、請求の範囲第17項に記載の方 法。 19.脂質低下剤、血小板凝集阻害剤、抗血栓剤、カルシウム遮断剤、アンギオ テンシン変換酵素(ACE)阻害剤、およびβ遮断剤からなる群から選択された 他の心臓血管剤と合わせて化合物を投与することを含む、請求の範囲第6項に記 載の方法。 20.脂質低下剤、血小板凝集阻害剤、抗血栓剤、カルシウム遮断剤、アンギオ テンシン変換酵素(ACE)阻害剤、およびβ遮断剤からなる群から選択された 他の心臓血管剤と合わせて化合物を投与することを含む、請求の範囲第15項に 記載の方法。 21.他の抗炎症剤と合わせて化合物を投与することを含む、請求の範囲第8項 に記載の方法。 22.他の抗炎症剤と合わせて化合物を投与することを含む、請求の範囲第16 項に記載の方法。 23.VCAM−1を抑制するための式(I)の化合物の使用であって、式(I )が の構造を有し、 XはO,S,SO,SO2、CH2、またはNHであり; スペーサーは−(CH2)n−、−(CH2)n−CO−、−(CH2)n−N−、 −(CH2)n−O−、−(CH2)n−S−、−(CH2O)−、−(OCH2)− 、−(SCH2)−、−(CH2S−)、−(アリール−O)−、−(O−アリー ル)−、(アルキル−O)−、−(O−アルキル)−からなる群から選択された 基であり; nは0、2,3,4,5,6,7,8,9、または10であり; Yは置換または非置換のアリール、置換または非置換のヘテロアリール、置換 または非置換のアルキル、置換または非置換のアルコキシ、置換または非置換の アルコキシアルキル、置換または非置換のアルキルチオ、置換または非置換のア ルキルチオアルキル、置換または非置換のアルキルスルフィニル、置換 または非置換のアルキルスルフィニルアルキル、置換または非置換のアルキルス ルフォニル、置換または非置換のアルキルスルフォニルアルキル、NH2、NH R、NR2、SO2−OH、OC(O)R、C(O)OH、C(O)OR、C(O )NH2、C(O)NHR、C(O)NR2、SO2NH2、SO2NHR、SO2N R2であり; Rがアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、置 換アルキニル、アリール、置換アリール、アルキル−COOH、アルキル−CO Oアルキル、アルキル−COOアリール、ヘテロアリール、置換ヘテロアリール であり、または窒素原子に結合した場合、隣接した2つのR基が共に5から7員 環を形成することができ; R1およびR2はそれぞれ独立に置換されたものでもよい直鎖、分枝、または環 状アルキルであり、アリール、置換アリール、ヘテロアリール、置換ヘテロアリ ール、アルカリル、またはアラルキルであり、R1またはR2基の置換基は水素、 ハロゲン、アルキル、ニトロ、アミノ、アルキルアミノ、ジアルキルアミノ、ア シル、およびアシロキシからなる群が選択され; R3およびR4はそれぞれ独立に、分子の望ましい特性に他の 悪影響を及ぼさない、H、ハロゲンまたはR1を含む任意の基である; 化合物または薬学的に容認されたその塩の使用。 24.請求の範囲第23項に記載の化合物の使用であって、 XはS、SO、またはSO2であり;スペーサーは−(CH2)n−または−( CH2)n−CO−であり;nは0〜10であり;Yはアリール、置換アリール、 ヘテロアリール、置換ヘテロアリール、NH2、NHR、アルキル、置換アルキ ル、アシルオキシおよび置換アシルオキシ;Rがアルキル、アルケニル、アルキ ニル、アリール、アルキル−COOH、アルキル−COOアルキル、アルキル− COOアリール、ヘテロアリールであり、またはニトロ置換ヘテロアリール、あ るいは窒素原子に結合している場合、隣接した2つのR基が共に5から7員環を 形成するために結合することができ;R1およびR2はそれぞれ独立に直鎖、分子 または環状C1-5アルキルであり;R3およびR4は独立にHである、 化合物または薬剤として許容されるその塩の使用。 25.式(I)の化合物からなる群から選択された請求の範囲第23項に記載の 化合物または薬剤として許容されるその塩の 使用であって、 X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−カルボキシメチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−ニトロフェニル; X=S;R1=L−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−カルボキシエチル X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=3,5−ジ−t−ブチル−4−カルボキシプロパノイロキシ; X=S;R1=t−ブチル、R2=t−ブチル;R3=H;R4=H;スペーサー= −CH2−;Y=4−カルボキシフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2;Y=1−アセチロキシ−1−メチルエチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4 =H;スペーサー=−CH2−;Y=3−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2,4−ジニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−トリフルオロメチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−カルボキシフラニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−(N,N−ジメチル)スルフォンアミドフェニル; X=SO;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー =−CH2−;Y=4−ニトロフェニル; X=SO2;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサ ー=−CH2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−アセチルオキシフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4 =H;スペーサー=−CH2−;Y=4−メチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−フルオロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=エチルスルホン酸; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−ジメチルアミノメチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)3−;Y=ジメチルアミノ; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)5−;Y=アセチルオキシ;および X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−(2−ヒドロキシ)エチルフェニル; である化合物またはその塩の使用。 26.VCMA−1によりもたらされる疾患の治療に対する式(I)の化合物の 使用であって、式(I)が の構造を有し、 XはO、S、SO、SO2、CH2、またはNHであり; スペーサーは−(CH2)n−、−(CH2)n−CO−、−(CH2)n−N−、 −(CH2)n−O−、−(CH2)n−S−、−(CH2O)−、−(OCH2)− 、−(SCH2)−、−(CH2S−)、−(アリール−O)−、−(O−アリー ル)−、(アルキル−O)−、−(O−アルキル)−の基から選択された基であ り; nは0、1、2、3、4、5、6、7、8、9、または10であり; Yは置換または非置換のアリール、置換または非置換のヘテロアリール、置換 または非置換のアルキル、置換または非置換のアルコキシ、置換または非置換の アルコキシアルキル、置換または非置換のアルキルチオ、置換または非置換のア ルキルチオアルキル、置換または非置換のアルキルスルフィニル、置換 または非置換のアルキルスルフィニルアルキル、置換または非置換のアルキルス ルフォニル、置換または非置換のアルキルスルフォニルアルキル、NH2、NH R、NR2、SO2−OH、OC(O)R、C(O)OH、C(O)OR、C(O )NH2、C(O)NHR、C(O)NR2、SO2NH2、SO2NHR、SO2N R2であり; Rはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、置 換アルキニル、アリール、置換アリール、アルキル−COOH、アルキル−CO Oアルキル、アルキル−COOアリール、ヘテロアリール、置換ヘテロアリール であり、または窒素原子に結合している場合、隣接した2つのR基が共に5から 7員環を形成することができ; R1およびR2はそれぞれ独立に置換されたものでもよい直鎖、分枝、または環 状アルキルであり、アリール、置換アリール、ヘテロアリール、置換ヘテロアリ ール、アルカリル、またはアラルキルであり、R1またはR2基の置換基は水素、 ハロゲン、アルキル、ニトロ、アミノ、アルキルアミノ、ジアルキルアミノ、ア シル、およびアシロキシからなる群から選択され; R3およびR4はそれぞれ独立に、分子の望ましい特性に他の 悪影響を及ぼさない、H、ハロゲンまたはR1を含む任意の基である; 化合物または薬学的に容認されたその塩の使用。 27.請求の範囲第26項に記載の式(I)の化合物または薬剤として許容され るその塩の使用であって、疾患が心臓血管疾患である使用。 28.請求の範囲第26項に記載の式(I)の化合物または薬剤として許容され るその塩の使用であって、疾患が炎症性疾患である使用。 29.請求の範囲第26項、第27項または第28項に記載の式(I)の化合物 の使用であって、 XはS、SO、またはSO2;スペーサーは−(CH2)n−または−(CH2)n −CO−;nが0〜10;Yがアリール、置換アリール、ヘテロアリール、置換 ヘテロアリール、NH2、NHR、NR2、アルキル、置換アルキル、アシルオキ シおよび置換アシルオキシであり;Rはアルキル、アルケニル、アルキニル、ア リール、アルキル−COOH、アルキル−COOアルキル、アルキル−COOア リール、ヘテロアリール、またはニトロ置換ヘテロアリール、あるいは窒素原子 に結合した場合、 隣接した2つのR基が共に5から7損環を形成することができ;R1およびR2は それぞれ独立に直鎖、分子または環状C1-5アルキルであり;R3およびR4は独 立にHである、 化合物または薬剤として許容されるその塩の使用。 30.式(I)の化合物からなる群から選択された請求の範囲第26項、第27 項または第28項に記載の式(I)の化合物または薬剤として許容されるその塩 の使用であって、 X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−カルボキシメチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−カルボキシエチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=3,5−ジ−t−ブチル−4−カルボキシプロパノイロキシ; X=S;R1=t−ブチル、R2=t−ブチル;R3=H;R4=H;スペーサー= −CH2−;Y=4−カルボキシフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=1−アセチロキシ−1−メチルエチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=3−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2,4−ジニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−トリフルオロメチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−カルボキシフラニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−(N,N−ジメチル)スルフォンアミドフェニル; X=SO;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー =−CH2−;Y=4−ニトロフェニル; X=SO2;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサ ー=−CH2−;Y=4−ニトロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=アセチルオキシフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−メチルフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=4−フルオロフェニル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=エチルスルホン酸; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −CH2−;Y=2−ジメチルアミノメチル; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)3−;Y=ジメチルアミノ; X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4=H;スペーサー= −(CH2)5−;Y=アセチルオキシ;かつ X=S;R1=t−ブチル;R2=t−ブチル、R3=H;R4 =H;スペーサー=−CH2−;Y=4−(2−ヒドロキシ)エチルフェニルで ある; 化合物またはその塩の使用。 31.VCAM−1の抑制のための式(II)の化合物または薬剤として許容さ れるその塩の使用であって、式(II)がの構造を有し、 Ra、Rb、RcおよびRdはそれぞれ独立に、分子の望ましい特性に悪影響を及 ぼさない、置換されたものでもよい水素、直鎖、分枝または環状アルキル、アリ ール、置換アリール、ヘテロアリール、置換ヘテロアリール、アルカリル、置換 アルカリル、アラルキルまたは置換アラルキルを含む任意の基であり; Ra、Rb、RcおよびRd基の置換基は水素、ハロゲン、アルキル、ニトロ、ア ミノ、ハロアルキル、アルキルアミノ、ジアルキルアミノ、アシルおよびアシル オキシからなる基から選 択され; Zは水素、アルキル、置換アルキル、アルケニル、置換アルケニル、アルキニ ル、置換アルキニル、アリール、アラルキル、アルカリル、ヘテロアリール、ヘ テロアラルキル、炭水化物基、−(CH2)−Re、−C(O)−Rg、および− C(O)−(CH2)n−Rhからなる群から選択され、(a)Ra、Rb、Rcおよ びRdがそれぞれt−ブチルの場合、Zは水素ではありえず、(b)Ra、Rb、 RcおよびRdがそれぞれt−ブチルの場合、Zはコハク酸残基でありえず; Reはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルコキルオキシ、アルコキシアルキル、置 換アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒドロキシ置 換アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、 アシルオキシ、置換アシルオキシ、COOH、COOR、−CH(OH)Rk、 ヒドロキシ、C(O)NH2、C(O)NHR、C(O)NR2からなる群から選 択され; Rgはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルキルオキ シ、アルコキシアルキル、置換アルコキシアルキル、NH2、NHR、NR2、モ ノ−またはポリヒドロキシ置換アルキル、アリール、置換アリール、ヘテロアリ ール、置換ヘテロアリールからなる群から選択され; Rhはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルキルオキシ、アルコキシアルキル、置換 アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒドロキシ置換 アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、ア シルオキシ、置換アシルオキシ、COOH、COOR、−CH(OH)Rk、ヒ ドロキシ、O−リン酸、C(O)NH2、C(O)NHR、C(O)NR2からな る基から選択され; または、代替実施形態では、Re、RgおよびRhはそれぞれ独立に、C(O) −スペーサー−SO3H(スペーサーが上記で定義するもの)、C(O)−スペ ーサー−SO3M(Mは、例えばナトリウムなど薬剤として許容される塩を形成 するために使用される金属)、C(O)−スペーサー−PO3H2、C(O)ース ペーサー−PO3M2、C(O)−スペーサー−PO3HM、C(O)−スペーサ ー−PO4H、C(O)−スペーサー−PO4 M、SO3M、−PO3H2、−PO3M2、−PO3HM、環状リン酸、ポリヒドロ キシアルキル、炭水化物基、C(O)−スペーサー−[O(C1-3アルキル)p]n (nは上記で定義したもの)を含むがそれだけに限らない、化合物の水溶性を 改善する置換基とすることかでき、pは1、2、または3、−[O(C1-3アル キル)p]n、カルボキシ低級アルキル、低級アルキルカルボニル低級アルキル、 N,N−ジアルキルアミノ低級アルキル、ピリジル低級アルキル、イミダゾリル 低級アルキル、モルフォリニル低級アルキル、ピロリジニル低級アルキル、チア ゾリニル低級アルキル、ピペリジニル低級アルキル、モルフォリニル低ヒドロキ シアルキル、N−ピリル、ピペラジニル低級アルキル、N−アルキルピペラジニ ル低級アルキル、トリアゾリル低級アルキル、テトラゾリル低級アルキル、テト ラゾリルアミノ低級アルキル、またはチアゾリル低級アルキルである、化合物ま たは薬剤として許容されるその塩の使用。 32.請求の範囲第31項に記載の式(II)の化合物または薬剤として許容さ れるその塩の使用であって、Ra、Rb、RcおよびRdがそれぞれ独立に水素また は直鎖、分枝もしくは環状C1-10アルキルであり;Zは水素、アルキル、置換ア ルキル、 アルケニル、置換アルケニル、アルキニル、置換アルキニル、炭水化物基、−( CH2)−Re−、−C(O)−Rg、および−C(O)−(CH2)n−Rhと薬剤 として許容されるその塩からなる群から選択され、(a)Ra、Rb、Rcおよび Rdがそれぞれt−ブチルの場合、Zは水素ではありえず、(b)Ra、Rb、Rc およびRdがそれぞれt−ブチルの場合、Zはコハク酸残基でありえない使用。 33.式(II)の化合物からなる群から選択された請求の範囲第31項に記載 の式(II)の化合物または薬剤として許容されるその塩の使用であって、 Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−ニトロフェニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(CH2)2−COOH; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(5−ニトロフラン−2−イル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−カルボキシプロピル; Ra=1−メチルエチル、Rb=t−ブチル、Rc=メチル、およびRd=メチル; Z=4−アミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−アミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシプロパノイル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;z=t−ブチルカルボニルオキシメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=H、およびRd=H;Z=4−アミノ ブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=H、およびRd=H;Z=3−カルボ キシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=カルボキシメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−(CONH2)エタノイル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アミノメチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=CO−(2−カルボキシエチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(2−メトキシカルボニルエチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アミノメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−カルボキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−カルボキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アンモニウムメチル(クロリド); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−2−オキシラニル−エチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=3−ヒドロキシメチルオキシラニ−2−イルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−(2−ヒドロキシ−2−オキシラニル)エトキシキシラン−2−イル メチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=オキシラニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−カルボキシメチルアミノプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3,4−トリヒドロキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−エトキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3−ジヒドロキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=エチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−エトキシカルボニルエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−N,N−ジメチルアミノフェネチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル(L−アルギニンエステル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−メトキシカルボニルプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−カルボキシエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=ガラクトピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−(N−N−ジエチルアミノ)プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−エトキシカルボニルエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=カルボキシメチルアミノカルボニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=1,3−ジカルボキシプロピルアミノカルボニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−(1,3−ジエトキシカルボニル)プロピルアミノ プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3−ジヒドロキシ−4−カルボキシメチルアミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−(5−アミノ−5−カルボキシ)プロピルアミノプ ロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−エチルカルボニルオキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−ヒドロキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=グルコピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−テトラゾリルプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシプロペニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CONH−(CH2)CH(NH2)COOH; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CONHCH(COOet)CH2CH2(COOet); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=グルコピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3,4,5,6−ペンタヒドロキシヘキサン; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−(2−ヒドロキシフェニルオキシホスホキシ)プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2,2−ジメチル−3−ヒドロキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−アセトキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−アセトキシ−3−ヒドロキシプロピル;かつ Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CH(OH)CH2NH(2,3,4,5,6−ペンタヒドロキシヘ キサンである; 使用。 34.VCAM−1によりもたらされる疾患の治療のための式(II)の化合物 または薬剤として許容されるその塩の使用であって、式(II)の化合物が の構造を有し、 Ra、Rb、RcおよびRdはそれぞれ独立に、分子の望ましい特性に悪影響を及 ぼさない、置換されたものでもよい水素、直鎖、分枝または環状アルキル、アリ ール、置換アリール、ヘテロアリール、置換ヘテロアリール、アルカリル、置換 アルカリル、アラルキルまたは置換アラルキルを含む任意の基であり; Ra、Rb、RcおよびRd基の置換基は水素、ハロゲン、アルキル、ニトロ、ア ミノ、ハロアルキル、アルキルアミノ、ジアルキルアミノ、アシルおよびアシル オキシからなる群から選択され; Zは水素、アルキル、置換アルキル、アルケニル、置換アルケニル、アルキニ ル、置換アルキニル、アリール、アラルキル、アルカリル、ヘテロアリール、ヘ テロアラルキル、炭水化物基、−(CH2)−Re、−C(O)−Rg、および− C(O) −(CH2)n−Rhからなる群から選択され、(a)Ra、Rb、RcおよびRdが それぞれt−ブチルの場合、Zは水素ではありえず、(b)Ra、Rb、Rcおよ びRdがそれぞれt−ブチルの場合、Zはコハク酸残基でありえず; Reはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルキルオキシ、アルコキシアルキル、置換 アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒドロキシ置換 アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、ア シルオキシ、置換アシルオキシ、COOH、COOR、−CH(OH)Rk、ヒ ドロキシ、C(O)NH2、C(O)NHR、C(O)NR2からなる群から選択 され; Rgはアルキル、置換アルキル、アルケニル、置換アルケニル、アルキニル、 置換アルキニル、アルコキシ、置換アルキルオキシ、アルコキシアルキル、置換 アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒドロキシ置換 アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロアリールから なる群から選択され; Rhはアルキル、置換アルキル、アルケニル、置換アルケニル、 アルキニル、置換アルキニル、アルコキシ、置換アルキルオキシ、アルコキシア ルキル、置換アルコキシアルキル、NH2、NHR、NR2、モノ−またはポリヒ ドロキシ置換アルキル、アリール、置換アリール、ヘテロアリール、置換ヘテロ アリール、アシルオキシ、置換アシルオキシ、COOH、COOR)−CH(O H)Rk、ヒドロキシ、O−リン酸、C(O)NH2、C(O)NHR、C(O) NR2からなる基から選択され; または、代替実施形態では、Re、RgおよびRhはそれぞれ独立にC(O)− スペーサー−SO3H(スペーサーが上記で定義したもの)、C(O)−スペー サー−SO3M(Mは、例えばナトリウムなど薬剤として許容される塩を形成す るために使用される金属)、C(O)−スペーサー−PO3H2、C(O)−スペ ーサー−PO3M2、C(O)−スペーサー−PO3HM、C(O)−スペーサー −PO4H、C(O)−スペーサー−PO4M、SO3M、−PO3H2、−PO3M2 、−PO3HM、環状リン酸、ポリヒドロキシアルキル、炭水化物基、C(O) −スペーサー−[O(C1-3アルキル)p]n(nは上記で定義したもの)を含む がそれだけには限らない、化合物の水溶性を改善する置換基とすることができ、 pは1、2、または3、−[O (C1-3アルキル)p]n、カルボキシ低級アルキル、低級アルキルカルボニル低 級アルキル、N,N−ジアルキルアミノ低級アルキル、ピリジル低級アルキル、 イミダゾリル低級アルキル、モルフォリニル低級アルキル、ピロリジニル低級ア ルキル、チアゾリニル低級アルキル、ピペリジニル低級アルキル、モルフォリニ ル低ヒドロキシアルキル、N−ピリル、ピペラジニル低級アルキル、N−アルキ ルピペラジニル低級アルキル、トリアゾリル低級アルキル、テトラゾリル低級ア ルキル、テトラゾリルアミノ低級アルキル、またはチアゾリル低級アルキルであ る、 化合物または薬剤として許容されるその塩の使用。 35.請求の範囲第34項に記載の式(II)の化合物の使用であって、疾患が 心臓血管疾患である使用。 36.請求の範囲第34項に記載の式(II)の化合物の使用であって、疾患が 炎症性疾患である使用。 37.請求の範囲第34項、第35項または第36項に記載の式(II)の化合 物の使用であって、Ra、Rb、RcおよびRdがそれぞれ独立に水素または直鎖、 分枝もしくは環状C1-10アルキルであり;Zは水素、アルキル、置換アルキル、 アルケニル、置換アルケニル、アルキニル、置換アルキニル、炭水化 物基、−(CH2)−Re−、−C(O)−Rg、および−C(O)−(CH2)n −Rhと薬剤として許容されるその塩からなる群から選択され、(a)Ra、Rb 、RcおよびRdがそれぞれt−ブチルの場合、Zは水素ではありえず、(b)Ra 、Rb、RcおよびRdがそれぞれt−ブチルの場合、Zはコハク酸残基でありえ ない使用。 38.式(II)の化合物からなる群から選択された請求の範囲第34項、第3 5項または第36項に記載の式(II)の化合物または薬剤として許容されるそ の塩の使用であって、 Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−ニトロフェニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(CH2)2−COOH; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(5−ニトロフラン−2−イル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−カルボキシプロピル; Ra=1−メチルエチル、Rb=t−ブチル、Rc=メチル、お よびRd=メチル;Z=4−アミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−アミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシプロパノイル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=t−ブチルカルボニルオキシメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=H、およびRd=H;Z=4−アミノ ブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=H、およびRd=H;Z=3−カルボ キシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=カルボキシメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−(CONH2)エタノイル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アミノメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(2−カルボキシエチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−(2−メトキシカルボニルエチル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アミノメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−カルボキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−カルボキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−アンモニウムメチル(クロリド); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−2−オキシラニル−エチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシメチルオキシラニ−2 −イルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−(2−ヒドロキシ−2−オキシラニル)エトキシオキシラン−2−イ ルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=オキシラニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−カルボキシメチルアミノプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3,4−トリヒドロキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−エトキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3−ジヒドロキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=エチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=2−エトキシカルボニルエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−N,N−ジメチルアミノフェネチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2−カルボキシエチル(L−アルギニンエステル); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−メトキシカルホニルプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−カルボキシエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=ガラクトピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−(N−N−ジエチルアミノ)プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=2−エトキシカルボニルエテニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=カルボキシメチルアミノカルボニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=1,3−ジカルボキシプロピルアミノカルボニルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−(1,3−ジエトキシカルボニル)プロピルアミノ プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3−ジヒドロキシ−4−カルボキシメチルアミノブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−(5−アミノ−5−カルボキシ)プロピルアミノプ ロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=4−エチルカルボニルオキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=4−ヒドロキシブチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=グルコピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−3−テトラゾリルプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=3−ヒドロキシプロペニル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CONH−(CH2)CH(NH2)COOH; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CONHCH(COOet)CH2CH2(COOet); Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=グルコピラノシルメチル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2,3,4,5,6−ペンタヒドロキシヘキサン; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およ びRd=t−ブチル;Z=CO−3−(2−ヒドロキシフェニルオキシホスホキ シ)プロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CO−2,2−ジメチル−3−ヒドロキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−ヒドロキシ−3−アセトキシプロピル; Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=2−アセトキシ−3−ヒドロキシプロピル;かつ Ra=t−ブチル、Rb=t−ブチル、Rc=t−ブチル、およびRd=t−ブチル ;Z=CH2CH(OH)CH2NH(2,3,4,5,6−ペンタヒドロキシヘ キサンである; 化合物またはその塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4702097P | 1997-05-14 | 1997-05-14 | |
US60/047,020 | 1997-05-14 | ||
PCT/US1998/009781 WO1998051662A2 (en) | 1997-05-14 | 1998-05-14 | Compounds and methods for the inhibition of the expression of vcam-1 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006116322A Division JP2006265257A (ja) | 1997-05-14 | 2006-04-20 | Vcam−1発現を阻害する化合物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002503227A true JP2002503227A (ja) | 2002-01-29 |
JP2002503227A5 JP2002503227A5 (ja) | 2006-08-24 |
JP3930056B2 JP3930056B2 (ja) | 2007-06-13 |
Family
ID=21946634
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54950298A Expired - Lifetime JP3930056B2 (ja) | 1997-05-14 | 1998-05-14 | Vcam−1発現を阻害する化合物および方法 |
JP54949898A Withdrawn JP2001524986A (ja) | 1997-05-14 | 1998-05-14 | 心血管性疾患および炎症性疾患を治療するためのプロブコールモノエステル類 |
JP2006115258A Pending JP2006232848A (ja) | 1997-05-14 | 2006-04-19 | 心血管性疾患および炎症性疾患を治療するためのプロブコールモノエステル類 |
JP2006116322A Pending JP2006265257A (ja) | 1997-05-14 | 2006-04-20 | Vcam−1発現を阻害する化合物および方法 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54949898A Withdrawn JP2001524986A (ja) | 1997-05-14 | 1998-05-14 | 心血管性疾患および炎症性疾患を治療するためのプロブコールモノエステル類 |
JP2006115258A Pending JP2006232848A (ja) | 1997-05-14 | 2006-04-19 | 心血管性疾患および炎症性疾患を治療するためのプロブコールモノエステル類 |
JP2006116322A Pending JP2006265257A (ja) | 1997-05-14 | 2006-04-20 | Vcam−1発現を阻害する化合物および方法 |
Country Status (26)
Country | Link |
---|---|
US (9) | US6147250A (ja) |
EP (2) | EP0981343B1 (ja) |
JP (4) | JP3930056B2 (ja) |
KR (5) | KR20010012504A (ja) |
CN (7) | CN1977836A (ja) |
AT (3) | ATE304350T1 (ja) |
AU (2) | AU750041B2 (ja) |
BR (2) | BR9809793A (ja) |
CA (3) | CA2289851C (ja) |
CY (1) | CY1107645T1 (ja) |
CZ (4) | CZ301313B6 (ja) |
DE (3) | DE69831566T2 (ja) |
DK (2) | DK1464639T3 (ja) |
EA (5) | EA009987B1 (ja) |
ES (3) | ES2248901T3 (ja) |
HK (2) | HK1024629A1 (ja) |
HU (2) | HUP0004592A3 (ja) |
ID (2) | ID23877A (ja) |
IL (7) | IL132797A0 (ja) |
NO (3) | NO327603B1 (ja) |
NZ (2) | NZ528906A (ja) |
PL (2) | PL194329B1 (ja) |
PT (1) | PT1464639E (ja) |
SK (4) | SK286392B6 (ja) |
TR (2) | TR199902802T2 (ja) |
WO (2) | WO1998051662A2 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516133A (ja) * | 2002-12-24 | 2006-06-22 | アースロン・リミテッド | Fc受容体調節化合物および組成物 |
JP2006516569A (ja) * | 2003-01-13 | 2006-07-06 | アセロジエニクス・インコーポレイテツド | プロブコールおよびその誘導体のエステルおよびエーテルの製造方法 |
JP2007512262A (ja) * | 2003-11-25 | 2007-05-17 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療のための新規な化合物 |
JP2007532538A (ja) * | 2004-04-09 | 2007-11-15 | キャンブレックス チャールズ シティ インコーポレイテッド | プロブコール誘導体の製造方法 |
JP2008505097A (ja) * | 2004-07-01 | 2008-02-21 | アセロジエニクス・インコーポレイテツド | 糖尿病性血管疾患を治療するための化合物および方法 |
JP2010090148A (ja) * | 2002-07-12 | 2010-04-22 | Atherogenics Inc | 低溶解性プロブコールエステル類およびエーテル類の新規な塩形態 |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ528906A (en) | 1997-05-14 | 2005-06-24 | Atherogenics Inc | Compounds and methods for the inhibition of the expression of VCAM-1 |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6852878B2 (en) * | 1998-05-14 | 2005-02-08 | Atherogenics, Inc. | Thioketals and thioethers for inhibiting the expression of VCAM-1 |
CN1261803A (zh) * | 1997-07-01 | 2000-08-02 | 埃瑟若詹尼克斯公司 | 抗氧化剂增强对细胞过度增生性疾病的治疗 |
CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
US6887712B1 (en) | 1998-11-09 | 2005-05-03 | Atherogenics, Inc. | Methods and compositions to lower plasma cholesterol levels |
CO5170498A1 (es) * | 1999-05-28 | 2002-06-27 | Abbott Lab | Biaril sulfonamidas son utiles como inhibidores de proliferacion celular |
US7361684B2 (en) * | 1999-06-28 | 2008-04-22 | Massachusetts Institute Of Technology | Screening of compounds for treatment of atherosclerosis and heart attack |
US6403637B1 (en) * | 1999-08-09 | 2002-06-11 | Univ Saint Louis | Methods of modulating matrix metalloproteinase activity and uses thereof |
JP2003528109A (ja) * | 2000-03-21 | 2003-09-24 | アセロジエニクス・インコーポレイテツド | Vcam−1の発現を阻害するためのチオケタール及びチオエーテル |
JP2003530383A (ja) | 2000-04-11 | 2003-10-14 | アセロジエニクス・インコーポレイテツド | 血漿hdlコレステロールレベルを上昇させ、hdl機能性を向上させる化合物および方法 |
US6323359B1 (en) * | 2000-05-02 | 2001-11-27 | Salsbury Chemicals, Inc. | Process for preparing probucol derivatives |
US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
JP2004501147A (ja) * | 2000-06-20 | 2004-01-15 | アセロジエニクス・インコーポレイテツド | 1,3−ビス−(置換フェニル)−2−プロペン−1−オン類およびvcam−1媒介障害を治療するためのそれらの使用 |
AUPQ872800A0 (en) * | 2000-07-12 | 2000-08-03 | Heart Research Institute, The | Compositions and methods for treating cardiovascular disorders |
CA2428753C (en) | 2000-11-17 | 2013-05-21 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
JP4334233B2 (ja) * | 2001-04-11 | 2009-09-30 | アセロジエニクス・インコーポレイテツド | プロブコールモノエステルによって血漿hdlコレステロールレベルを上昇させ、hdlの機能性を改善するための方法 |
CA2464717A1 (en) * | 2001-10-25 | 2003-05-15 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
IL161741A0 (en) * | 2001-11-09 | 2005-11-20 | Atherogenics Inc | Methods of reversing and preventingcardiovascular pathologies |
HUP0500165A2 (en) | 2001-12-19 | 2006-09-28 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
US6939554B2 (en) * | 2002-02-05 | 2005-09-06 | Michigan Biotechnology Institute | Antimicrobial polymer |
ITMI20020597A1 (it) | 2002-03-22 | 2003-09-22 | Nicox Sa | Derivati del probucolo |
US7208467B2 (en) | 2002-06-07 | 2007-04-24 | Monty Krieger | Lipid-altering compositions for the treatment of infertility |
US20050163821A1 (en) * | 2002-08-02 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting Biodegradable Stent and Delivery Means |
AU2003266165A1 (en) * | 2002-09-13 | 2004-04-30 | Hossein Dovlatabadi | Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels |
AU2003288925A1 (en) * | 2002-10-08 | 2004-05-04 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009848A (es) * | 2003-03-17 | 2005-12-06 | Japan Tobacco Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo. |
WO2004108094A2 (en) | 2003-06-06 | 2004-12-16 | Atherogenics, Inc. | Sulfonamide-substituted chalcone derivatives and their use to treat diseases |
WO2005025492A2 (en) * | 2003-07-07 | 2005-03-24 | Emory University | Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease |
US20050026879A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
JP2007509054A (ja) * | 2003-10-17 | 2007-04-12 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 血管健康を促進するシリルフェノール |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
JP5196787B2 (ja) * | 2003-11-14 | 2013-05-15 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾患を治療するためのα,β−不飽和スルホキシド |
US20060025481A1 (en) * | 2004-02-09 | 2006-02-02 | Strange Matthew L | Process for preparation of probucol derivatives and polymorphic forms thereof |
WO2005112914A2 (en) * | 2004-04-20 | 2005-12-01 | Atherogenics, Inc. | Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease |
US7294737B2 (en) * | 2004-04-20 | 2007-11-13 | Atherogenics, Inc. | Process of preparing esters and ethers of probucol and derivatives thereof |
US7183285B2 (en) * | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050272770A1 (en) * | 2004-04-29 | 2005-12-08 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US7199126B2 (en) * | 2004-04-29 | 2007-04-03 | Pharmix Corporation | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20050282883A1 (en) * | 2004-04-29 | 2005-12-22 | John Griffin | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
US20060111436A1 (en) * | 2004-11-23 | 2006-05-25 | John Griffin | Compositions and treatments for modulating kinase and/or HMG-CoA reductase |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
EP1844009A4 (en) * | 2004-12-17 | 2010-04-21 | Roland O Stocker | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CARDIAC DISORDER |
US7345191B2 (en) * | 2005-02-26 | 2008-03-18 | Cambrex Charles City, Inc. | Process for preparation of probucol derivatives |
CA2606414A1 (en) | 2005-04-21 | 2006-11-02 | Atherogenics, Inc. | Process for the separation of probucol derivatives |
US20070015779A1 (en) * | 2005-04-29 | 2007-01-18 | John Griffin | Compositions and treatments for inhibiting kinase and/or hmg-coa reductase |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US20060269579A1 (en) * | 2005-05-25 | 2006-11-30 | Musculoskeletal Research Llc | Compositions for treating osteoarthritis |
US7767710B2 (en) | 2005-05-25 | 2010-08-03 | Calosyn Pharma, Inc. | Method for treating osteoarthritis |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
WO2007142581A1 (en) * | 2006-06-07 | 2007-12-13 | Astrazeneca Ab | Combination product for the treatment or prevention of dyslipidaemia |
BRPI0809423A2 (pt) | 2007-03-26 | 2014-09-09 | Salutria Pharmaceuticals Llc | Usos e composições de derivados de probucol para o tratamento de diabetes |
US20080280985A1 (en) * | 2007-03-27 | 2008-11-13 | Scott Robert A D | Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US7897776B2 (en) | 2007-04-23 | 2011-03-01 | Salutria Pharmaceuticals Llc | Sulfonamide containing compounds for treatment of inflammatory disorders |
JP2010531354A (ja) * | 2007-06-26 | 2010-09-24 | アストラゼネカ アクチボラグ | カルボキシ基で一置換されたプロブコール誘導体の単離方法 |
EP2170847A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
KR20100051625A (ko) * | 2007-06-28 | 2010-05-17 | 인터벳 인터내셔널 비.브이. | Cb1 길항제로서의 치환된 피페라진 |
WO2009042854A1 (en) * | 2007-09-26 | 2009-04-02 | Musculoskeletal Research Llc | Ion-channel regulator compositions and methods of using same |
US7967795B1 (en) | 2010-01-19 | 2011-06-28 | Lamodel Ltd. | Cartridge interface assembly with driving plunger |
EP2195052B1 (en) | 2007-10-02 | 2019-09-04 | Medimop Medical Projects Ltd. | External drug pump |
US10420880B2 (en) | 2007-10-02 | 2019-09-24 | West Pharma. Services IL, Ltd. | Key for securing components of a drug delivery system during assembly and/or transport and methods of using same |
US9656019B2 (en) | 2007-10-02 | 2017-05-23 | Medimop Medical Projects Ltd. | Apparatuses for securing components of a drug delivery system during transport and methods of using same |
US9345836B2 (en) | 2007-10-02 | 2016-05-24 | Medimop Medical Projects Ltd. | Disengagement resistant telescoping assembly and unidirectional method of assembly for such |
CA2703203C (en) | 2007-10-22 | 2015-12-15 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
JP5669729B2 (ja) * | 2008-05-13 | 2015-02-12 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダGenmedica Therapeutics Sl | 代謝性障害を治療するのに有用なサリチレートコンジュゲート |
AU2009249237A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
WO2010009195A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
US9393369B2 (en) | 2008-09-15 | 2016-07-19 | Medimop Medical Projects Ltd. | Stabilized pen injector |
US20100145305A1 (en) * | 2008-11-10 | 2010-06-10 | Ruth Alon | Low volume accurate injector |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
WO2010075271A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
JP2012513469A (ja) | 2008-12-23 | 2012-06-14 | シェーリング コーポレイション | ピリミジン誘導体及びその使用法 |
WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
US8152779B2 (en) * | 2008-12-30 | 2012-04-10 | Medimop Medical Projects Ltd. | Needle assembly for drug pump |
CA2755069A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
JP2012520343A (ja) * | 2009-03-16 | 2012-09-06 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 代謝障害治療のための併用療法 |
BRPI1009315B8 (pt) | 2009-03-18 | 2021-05-25 | Resverlogix Corp | composto anti-flamatórios e suas composições farmacêuticas |
AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
PL2437606T3 (pl) | 2009-05-18 | 2017-07-31 | Telomerase Activation Sciences, Inc. | Kompozycje i sposoby zwiększania aktywności telomerazy |
US10071196B2 (en) | 2012-05-15 | 2018-09-11 | West Pharma. Services IL, Ltd. | Method for selectively powering a battery-operated drug-delivery device and device therefor |
US8157769B2 (en) | 2009-09-15 | 2012-04-17 | Medimop Medical Projects Ltd. | Cartridge insertion assembly for drug delivery system |
US10071198B2 (en) | 2012-11-02 | 2018-09-11 | West Pharma. Servicees IL, Ltd. | Adhesive structure for medical device |
AU2010313469A1 (en) | 2009-10-29 | 2012-06-07 | Merck Sharp & Dohme Corp. | Bridged Bicyclic Piperidine Derivatives and methods of use thereof |
WO2011062889A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Pyrimidine ether derivatives and methods of use thereof |
WO2011062885A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Fused bicyclic pyrimidine derivatives and methods of use thereof |
WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
US8348898B2 (en) | 2010-01-19 | 2013-01-08 | Medimop Medical Projects Ltd. | Automatic needle for drug pump |
WO2011141907A1 (en) | 2010-05-10 | 2011-11-17 | Medimop Medical Projects Ltd. | Low volume accurate injector |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
USD702834S1 (en) | 2011-03-22 | 2014-04-15 | Medimop Medical Projects Ltd. | Cartridge for use in injection device |
US9072827B2 (en) | 2012-03-26 | 2015-07-07 | Medimop Medical Projects Ltd. | Fail safe point protector for needle safety flap |
US9421323B2 (en) | 2013-01-03 | 2016-08-23 | Medimop Medical Projects Ltd. | Door and doorstop for portable one use drug delivery apparatus |
KR20160023638A (ko) | 2013-02-28 | 2016-03-03 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 줄기세포를 이동하기 위한 방법 및 조성물 |
US9011164B2 (en) | 2013-04-30 | 2015-04-21 | Medimop Medical Projects Ltd. | Clip contact for easy installation of printed circuit board PCB |
US10293120B2 (en) | 2015-04-10 | 2019-05-21 | West Pharma. Services IL, Ltd. | Redundant injection device status indication |
US10149943B2 (en) | 2015-05-29 | 2018-12-11 | West Pharma. Services IL, Ltd. | Linear rotation stabilizer for a telescoping syringe stopper driverdriving assembly |
EP4252798A3 (en) | 2015-06-04 | 2023-10-25 | Medimop Medical Projects Ltd. | Cartridge insertion for drug delivery device |
US10576207B2 (en) | 2015-10-09 | 2020-03-03 | West Pharma. Services IL, Ltd. | Angled syringe patch injector |
US9987432B2 (en) | 2015-09-22 | 2018-06-05 | West Pharma. Services IL, Ltd. | Rotation resistant friction adapter for plunger driver of drug delivery device |
US10086145B2 (en) | 2015-09-22 | 2018-10-02 | West Pharma Services Il, Ltd. | Rotation resistant friction adapter for plunger driver of drug delivery device |
CN108430536B (zh) | 2015-10-09 | 2022-04-08 | 西医药服务以色列分公司 | 填充定制注射筒的方法 |
US11311674B2 (en) | 2016-01-21 | 2022-04-26 | West Pharma. Services IL, Ltd. | Medicament delivery device comprising a visual indicator |
JP6513297B2 (ja) | 2016-01-21 | 2019-05-22 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 自動注射器、受け入れフレーム及び自動注射器におけるカートリッジの接続方法 |
WO2017127215A1 (en) | 2016-01-21 | 2017-07-27 | Medimop Medical Projects Ltd. | Needle insertion and retraction mechanism |
WO2017161076A1 (en) | 2016-03-16 | 2017-09-21 | Medimop Medical Projects Ltd. | Staged telescopic screw assembly having different visual indicators |
US10376647B2 (en) | 2016-03-18 | 2019-08-13 | West Pharma. Services IL, Ltd. | Anti-rotation mechanism for telescopic screw assembly |
JP6957525B2 (ja) | 2016-06-02 | 2021-11-02 | ウェスト ファーマ サービシーズ イスラエル リミテッド | 3つの位置による針の退避 |
US9650332B1 (en) * | 2016-06-16 | 2017-05-16 | Yong Xu | Prodrug of probucol and method for preparing the same |
JP7059251B2 (ja) | 2016-08-01 | 2022-04-25 | ウェスト ファーマ サービシーズ イスラエル リミテッド | ドアの半閉じを防止するスプリング |
US11338090B2 (en) | 2016-08-01 | 2022-05-24 | West Pharma. Services IL, Ltd. | Anti-rotation cartridge pin |
CN106905208B (zh) * | 2017-02-27 | 2018-09-07 | 江西瑞雅药业有限公司 | 普罗布考前药及其制备方法和药物组合物 |
WO2018222521A1 (en) | 2017-05-30 | 2018-12-06 | West Pharma. Services IL, Ltd. | Modular drive train for wearable injector |
US11857767B2 (en) | 2017-12-22 | 2024-01-02 | West Pharma. Services IL, Ltd. | Injector usable with different dimension cartridges |
CN108299263B (zh) | 2018-01-30 | 2020-12-01 | 北京德默高科医药技术有限公司 | 一种普罗布考衍生物及其制备方法与应用 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3179701A (en) * | 1962-05-14 | 1965-04-20 | Shell Oil Co | (3, 5-dialkyl-4-hydroxyphenyl) (3, 5-dialkyl-4-hydroxybenzyl) sulfides |
US4115590A (en) * | 1964-02-26 | 1978-09-19 | Ethyl Corporation | Binuclear phenols for reducing plasma lipid levels |
GB1136539A (en) * | 1966-12-13 | 1968-12-11 | Uniroyal Inc | Phenolic sulphides |
US3485843A (en) * | 1967-05-11 | 1969-12-23 | Dow Chemical Co | Piperazine adducts of ketone mercaptoles |
GB1199871A (en) * | 1967-05-11 | 1970-07-22 | Consolidation Coal Co | Improvements in or relating to Sulfur-Containing Bisphenols |
GB1148550A (en) * | 1967-12-02 | 1969-04-16 | Uniroyal Inc | Substituted benzylphenyl sulfides and their use as antioxidants |
US3479407A (en) * | 1968-11-06 | 1969-11-18 | Consolidation Coal Co | Sulfurization of 2,6-di-tert-butylphenol |
US3576883A (en) * | 1969-06-30 | 1971-04-27 | Consolidation Coal Co | Alkylidenedithiobisphenols |
DE2104524C3 (de) | 1970-09-16 | 1980-08-07 | Veb Kombinat Umformtechnik Herbert Warnke Erfurt, Ddr 5000 Erfurt | Hydraulische Überlastsicherung |
FR2130975A5 (en) * | 1971-03-29 | 1972-11-10 | Aries Robert | Bis(4-(phenoxyalkanoyloxy)-phenylthio)alkanes - hypolipemics hypocholesterolemics |
FR2133024A5 (en) * | 1971-04-06 | 1972-11-24 | Aries Robert | Bis-(4-nicotinoyloxyphenylthio) propanes - with hypocholesterolaemic and hypolipaemic activity |
FR2134810A5 (en) * | 1971-04-21 | 1972-12-08 | Aries Robert | Bis-(3-alkyl-5-t-alkyl-4-(thiazole-5-carboxy)phenylthio) alcanes - - with hypocholesterolaemic and hypolipaemic activity |
FR2140771A5 (en) * | 1971-06-07 | 1973-01-19 | Aries Robert | Tetralinyl phenoxy alkanoic esters - of bis hydroxyphenylthio alkanes, hypolipemics etc |
FR2140769A5 (en) * | 1971-06-07 | 1973-01-19 | Aries Robert | Benzofuryloxy alkanoic derivs of probucol - hypocholesterolemic and hypolipemic agents |
FR2168137A1 (en) * | 1972-01-17 | 1973-08-31 | Dynachim Sarl | Bis 4-hydroxyphenylthioalkane esters - with hypocholesterolaemic and hypolipaemic activities |
JPS4975552A (ja) * | 1972-11-20 | 1974-07-20 | ||
US3952064A (en) * | 1973-03-12 | 1976-04-20 | Crown Zellerbach Corporation | Process for producing mercaptophenols |
US4029812A (en) * | 1976-02-18 | 1977-06-14 | The Dow Chemical Company | Novel hypolipidemic 2-(3,5-di-tert-butyl-4-hydroxyphenyl)thio carboxamides |
JPS52125170A (en) * | 1976-04-12 | 1977-10-20 | Yoshitomi Pharmaceut Ind Ltd | Pyridine derivatives |
US4968514A (en) * | 1984-12-11 | 1990-11-06 | Forbes Polytech, Inc. | Beer bottle with fully reacted thermoplastic polyurethane crown capliner |
AU584669B2 (en) * | 1985-02-04 | 1989-06-01 | G.D. Searle & Co. | Novel disubstituted 4-hydroxyphenylthio anilides |
US4679520A (en) | 1985-06-10 | 1987-07-14 | Harken Olaf T | Mainsail reefing and furling device and method |
DE3530256A1 (de) | 1985-08-23 | 1987-02-26 | Merrell Dow Pharma | Verwendung von probucol bei der behandlung von herzarrhythmie |
US4755524A (en) * | 1986-01-31 | 1988-07-05 | G. D. Searle & Co. | Novel phenolic thioethers as inhibitors of 5-lipoxygenase |
DE3625279A1 (de) | 1986-07-25 | 1988-02-04 | Merrell Dow Pharma | Verwendung von probucol zur vorbeugung und behandlung von erkrankungen des herzens |
DE3869202D1 (de) * | 1987-03-17 | 1992-04-23 | Merrell Dow Pharma | Alkylidendithiobis (substituierte) phenolen zur hemmung der freisetzung von interleukin-1 und zur linderung von interleukin-1 vermittelten krankheiten. |
US4975467A (en) | 1987-03-17 | 1990-12-04 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release and alleviating interleukin-1 mediated conditions |
US4752616A (en) * | 1987-06-29 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use |
US5066822A (en) | 1987-11-13 | 1991-11-19 | Riker Laboratories, Inc | Di-t-butylphenols substituted by an alkoxy or benzyloxy group or a benzylthio group |
NZ226621A (en) * | 1987-11-13 | 1991-12-23 | Riker Laboratories Inc | Di-tert butyl phenols substituted by alkoxy, benzyloxy, or benzylthio groups; pharmaceutical compositions containing them |
US4968710A (en) | 1987-11-13 | 1990-11-06 | Riker Laboratories, Inc. | Substituted di-t-butylphenols and anti-allergic use thereof |
CH675422A5 (ja) | 1988-03-31 | 1990-09-28 | Symphar Sa | |
JP2754039B2 (ja) | 1988-06-24 | 1998-05-20 | 塩野義製薬株式会社 | ジ―tert―ブチルヒドロキシフェニルチオ誘導体 |
JP2627003B2 (ja) * | 1989-01-25 | 1997-07-02 | 塩野義製薬株式会社 | ジーtert―ブチルヒドロキシフェニルチオ誘導体 |
US5527945A (en) | 1989-02-10 | 1996-06-18 | Basf Aktiengesellschaft | Diphenylheteroalkyl derivatives, the preparation thereof and drugs and cosmetics prepared therefrom |
JP3065636B2 (ja) * | 1989-06-29 | 2000-07-17 | 塩野義製薬株式会社 | [ジ―tert―ブチル(ヒドロキシ)フェニルチオ]置換ヒドロキサム酸誘導体 |
CA2017956A1 (en) * | 1989-07-06 | 1991-01-06 | Werner Bollag | Use of retinoids |
DE3929913A1 (de) | 1989-09-08 | 1991-04-04 | Hoechst Ag | 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte |
US5115250A (en) * | 1990-01-12 | 1992-05-19 | Hewlett-Packard Company | Wiper for ink-jet printhead |
US5061734A (en) | 1990-05-09 | 1991-10-29 | Merrell Dow Pharmaceuticals Inc. | Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis |
US5112870A (en) | 1990-05-09 | 1992-05-12 | Merrell Dow Pharmaceuticals Inc. | Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5155250A (en) * | 1990-07-05 | 1992-10-13 | Merrell Dow Pharmaceuticals Inc. | 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents |
US5085777A (en) * | 1990-08-31 | 1992-02-04 | E. I. Du Pont De Nemours And Company | Reverse osmosis membranes of polyamideurethane |
FR2666583B1 (fr) * | 1990-09-06 | 1994-09-09 | Adir | Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant. |
RU2024509C1 (ru) * | 1991-05-07 | 1994-12-15 | Всероссийский научный центр по безопасности биологически активных веществ | Производные 9-аминоакридина или их соли с органическими или неорганическими кислотами, проявляющие психотропную, антиамнестическую и липидрегулирующую активность |
GB9115951D0 (en) | 1991-07-24 | 1991-09-11 | Pfizer Ltd | Indoles |
DE59309630D1 (de) | 1992-02-05 | 1999-07-08 | Boehringer Ingelheim Pharma | Neue amidinderivate, ihre herstellung und verwendung als arzneimittel mit ltb4-antagonistischer wirkung |
US5262439A (en) * | 1992-04-30 | 1993-11-16 | The Regents Of The University Of California | Soluble analogs of probucol |
US5310949A (en) | 1992-09-02 | 1994-05-10 | Merck & Co., Inc. | Cholesterol lowering compounds |
GB9220571D0 (en) | 1992-09-30 | 1992-11-11 | Ici Plc | Quinazoline derivatives |
US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5783596A (en) * | 1992-10-30 | 1998-07-21 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
US5662934A (en) * | 1993-01-05 | 1997-09-02 | Najarian; Thomas | Compositions and methods for lowering cholesterol while maintaining antioxidant levels |
US5585235A (en) | 1993-04-13 | 1996-12-17 | Diagnescent Technologies, Inc. | Fluorescent assay and method that corrects for spectral interference |
FR2704224B1 (fr) * | 1993-04-20 | 1995-08-25 | Adir | Nouveaux acides et esters phénoxy isobutyriques substitués. |
JPH06312978A (ja) * | 1993-04-30 | 1994-11-08 | Japan Tobacco Inc | ホスホリパーゼa2阻害活性を有する新規フタルイミド誘導体 |
US5411741A (en) | 1993-07-29 | 1995-05-02 | Zaias; Nardo | Method and composition for skin depigmentation |
GB9320113D0 (en) | 1993-09-29 | 1993-11-17 | Zeneca Ltd | Tricyclic derivatives |
WO1995015760A1 (en) * | 1993-12-10 | 1995-06-15 | Merrell Pharmaceuticals Inc. | Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols |
US5426196A (en) | 1993-12-22 | 1995-06-20 | Glaxo Inc. | Synthesis of diaryl methanes |
JPH07328425A (ja) * | 1994-06-03 | 1995-12-19 | Toshiba Corp | プラズマ化学反応装置 |
US5693337A (en) | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
US5635514A (en) * | 1994-10-25 | 1997-06-03 | G. D. Searle & Company | Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors |
US5792787A (en) * | 1995-06-07 | 1998-08-11 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
JPH0959258A (ja) * | 1995-08-11 | 1997-03-04 | Ono Pharmaceut Co Ltd | グアニジル誘導体 |
FR2738817B1 (fr) * | 1995-09-14 | 1997-10-17 | Adir | Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO1997015546A1 (fr) * | 1995-10-26 | 1997-05-01 | Nippon Shinyaku Co., Ltd. | Derives d'acide carboxylique et compositions pharmaceutiques |
EP0876366B1 (en) | 1996-01-15 | 2001-07-25 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
US5608095A (en) * | 1996-04-30 | 1997-03-04 | Hoechst Marion Roussel, Inc. | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents |
KR20000022040A (ko) | 1996-06-20 | 2000-04-25 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도 |
JP4267705B2 (ja) * | 1996-11-20 | 2009-05-27 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 抗酸化剤として有用な置換フェノールおよびチオフェノール |
WO1998030255A2 (en) | 1997-01-09 | 1998-07-16 | Localmed, Inc. | Localized intravascular delivery of antioxidant substances for inhibition of restenosis in recanalized blood vessels |
GB9705502D0 (en) | 1997-03-17 | 1997-05-07 | Univ Wales Swansea The | Chlorination or aromatic compounds and catalysts therefor |
WO1998042327A2 (en) | 1997-03-24 | 1998-10-01 | Cote Gilles | Vascular remodeling agent |
NZ528906A (en) | 1997-05-14 | 2005-06-24 | Atherogenics Inc | Compounds and methods for the inhibition of the expression of VCAM-1 |
US6852878B2 (en) * | 1998-05-14 | 2005-02-08 | Atherogenics, Inc. | Thioketals and thioethers for inhibiting the expression of VCAM-1 |
US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
CN1261803A (zh) * | 1997-07-01 | 2000-08-02 | 埃瑟若詹尼克斯公司 | 抗氧化剂增强对细胞过度增生性疾病的治疗 |
CA2304505A1 (en) | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
AU1387399A (en) | 1997-11-10 | 1999-05-31 | Vyrex Corporation | Probucol esters and uses thereof |
FR2785284B1 (fr) | 1998-11-02 | 2000-12-01 | Galderma Res & Dev | Analogues de la vitamine d |
DE19850532A1 (de) | 1998-11-03 | 2000-05-04 | Nematel Dr Rudolf Eidenschink | Bisphenylthio-Verbindungen |
AU1911200A (en) * | 1998-11-09 | 2000-05-29 | Atherogenics, Inc. | Methods and compositions to lower plasma cholesterol levels |
ATE238287T1 (de) | 1998-11-23 | 2003-05-15 | Janssen Pharmaceutica Nv | 6-azauracilderivate als il-5 inhibitoren |
KR100870508B1 (ko) | 1999-03-10 | 2008-11-25 | 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 지방 유래 간세포 및 격자 |
ATE329596T1 (de) | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
JP2003528109A (ja) * | 2000-03-21 | 2003-09-24 | アセロジエニクス・インコーポレイテツド | Vcam−1の発現を阻害するためのチオケタール及びチオエーテル |
AU2001247649A1 (en) | 2000-03-21 | 2001-10-30 | Atherogenics, Inc | N-substituted dithiocarbamates for the treatment of biological disorders |
US6323359B1 (en) | 2000-05-02 | 2001-11-27 | Salsbury Chemicals, Inc. | Process for preparing probucol derivatives |
JP4334233B2 (ja) | 2001-04-11 | 2009-09-30 | アセロジエニクス・インコーポレイテツド | プロブコールモノエステルによって血漿hdlコレステロールレベルを上昇させ、hdlの機能性を改善するための方法 |
WO2002092660A2 (en) | 2001-05-14 | 2002-11-21 | Omnova Soltions Inc | Polymeric surfactants derived from cyclic monomers having pendant fluorinated carbon groups |
US7187870B2 (en) * | 2003-10-15 | 2007-03-06 | Oewaves, Inc. | Tunable balanced opto-electronic filters and applications in opto-electronic oscillators |
-
1998
- 1998-05-14 NZ NZ528906A patent/NZ528906A/en not_active IP Right Cessation
- 1998-05-14 CA CA002289851A patent/CA2289851C/en not_active Expired - Fee Related
- 1998-05-14 AU AU74851/98A patent/AU750041B2/en not_active Ceased
- 1998-05-14 ES ES98923411T patent/ES2248901T3/es not_active Expired - Lifetime
- 1998-05-14 ES ES98922264T patent/ES2241139T3/es not_active Expired - Lifetime
- 1998-05-14 CN CNA2006101016892A patent/CN1977836A/zh active Pending
- 1998-05-14 SK SK1532-99A patent/SK286392B6/sk not_active IP Right Cessation
- 1998-05-14 IL IL13279798A patent/IL132797A0/xx not_active IP Right Cessation
- 1998-05-14 KR KR1019997010459A patent/KR20010012504A/ko not_active Application Discontinuation
- 1998-05-14 SK SK1531-99A patent/SK285695B6/sk not_active IP Right Cessation
- 1998-05-14 CN CNA2007101939040A patent/CN101284808A/zh active Pending
- 1998-05-14 IL IL16456898A patent/IL164568A0/xx unknown
- 1998-05-14 SK SK50038-2007A patent/SK286766B6/sk not_active IP Right Cessation
- 1998-05-14 WO PCT/US1998/009781 patent/WO1998051662A2/en active Application Filing
- 1998-05-14 CN CNB988071711A patent/CN1200704C/zh not_active Expired - Fee Related
- 1998-05-14 PL PL98336788A patent/PL194329B1/pl not_active IP Right Cessation
- 1998-05-14 DE DE69831566T patent/DE69831566T2/de not_active Expired - Fee Related
- 1998-05-14 JP JP54950298A patent/JP3930056B2/ja not_active Expired - Lifetime
- 1998-05-14 SK SK5028-2006A patent/SK286674B6/sk not_active IP Right Cessation
- 1998-05-14 PL PL343904A patent/PL207885B1/pl not_active IP Right Cessation
- 1998-05-14 KR KR1019997010458A patent/KR100882335B1/ko not_active IP Right Cessation
- 1998-05-14 HU HU0004592A patent/HUP0004592A3/hu unknown
- 1998-05-14 WO PCT/US1998/009773 patent/WO1998051289A2/en active Application Filing
- 1998-05-14 IL IL13279898A patent/IL132798A0/xx active IP Right Grant
- 1998-05-14 AT AT98923411T patent/ATE304350T1/de not_active IP Right Cessation
- 1998-05-14 HU HU0004230A patent/HU226611B1/hu not_active IP Right Cessation
- 1998-05-14 ID IDW991584A patent/ID23877A/id unknown
- 1998-05-14 DE DE69837295T patent/DE69837295T2/de not_active Expired - Lifetime
- 1998-05-14 EP EP98923411A patent/EP0981343B1/en not_active Expired - Lifetime
- 1998-05-14 EP EP98922264A patent/EP0994853B1/en not_active Expired - Lifetime
- 1998-05-14 CZ CZ20060388A patent/CZ301313B6/cs not_active IP Right Cessation
- 1998-05-14 CN CNB98807169XA patent/CN100453530C/zh not_active Expired - Fee Related
- 1998-05-14 EA EA200500249A patent/EA009987B1/ru not_active IP Right Cessation
- 1998-05-14 ID IDW991582A patent/ID29158A/id unknown
- 1998-05-14 EA EA200800375A patent/EA200800375A1/ru unknown
- 1998-05-14 EA EA200601059A patent/EA012847B1/ru not_active IP Right Cessation
- 1998-05-14 PT PT04075141T patent/PT1464639E/pt unknown
- 1998-05-14 KR KR1020067027007A patent/KR20070008725A/ko not_active Application Discontinuation
- 1998-05-14 CN CNB031530664A patent/CN1287783C/zh not_active Expired - Fee Related
- 1998-05-14 NZ NZ501069A patent/NZ501069A/xx unknown
- 1998-05-14 US US09/079,213 patent/US6147250A/en not_active Expired - Lifetime
- 1998-05-14 EA EA199901026A patent/EA009370B1/ru not_active IP Right Cessation
- 1998-05-14 EA EA199901027A patent/EA010183B1/ru not_active IP Right Cessation
- 1998-05-14 TR TR1999/02802T patent/TR199902802T2/xx unknown
- 1998-05-14 AT AT04075141T patent/ATE356113T1/de active
- 1998-05-14 CN CN2006101018440A patent/CN1977837B/zh not_active Expired - Fee Related
- 1998-05-14 CA CA002292388A patent/CA2292388C/en not_active Expired - Fee Related
- 1998-05-14 TR TR1999/02803T patent/TR199902803T2/xx unknown
- 1998-05-14 US US09/078,935 patent/US6121319A/en not_active Expired - Lifetime
- 1998-05-14 DE DE69829966T patent/DE69829966T2/de not_active Expired - Fee Related
- 1998-05-14 KR KR1020087015303A patent/KR100953990B1/ko not_active IP Right Cessation
- 1998-05-14 BR BR9809793-8A patent/BR9809793A/pt not_active Application Discontinuation
- 1998-05-14 CZ CZ20090366A patent/CZ301985B6/cs not_active IP Right Cessation
- 1998-05-14 AU AU75711/98A patent/AU747801C/en not_active Ceased
- 1998-05-14 BR BR9809819-5A patent/BR9809819A/pt not_active Application Discontinuation
- 1998-05-14 ES ES04075141T patent/ES2283933T3/es not_active Expired - Lifetime
- 1998-05-14 DK DK04075141T patent/DK1464639T3/da active
- 1998-05-14 CN CNB031530672A patent/CN1275596C/zh not_active Expired - Fee Related
- 1998-05-14 JP JP54949898A patent/JP2001524986A/ja not_active Withdrawn
- 1998-05-14 CA CA002428130A patent/CA2428130A1/en not_active Abandoned
- 1998-05-14 CZ CZ0402499A patent/CZ301302B6/cs not_active IP Right Cessation
- 1998-05-14 AT AT98922264T patent/ATE294158T1/de not_active IP Right Cessation
- 1998-05-14 CZ CZ0402399A patent/CZ301183B6/cs not_active IP Right Cessation
- 1998-05-14 DK DK98923411T patent/DK0981343T3/da active
-
1999
- 1999-08-06 US US09/370,046 patent/US6548699B1/en not_active Expired - Fee Related
- 1999-11-08 IL IL132798A patent/IL132798A/en not_active IP Right Cessation
- 1999-11-12 NO NO19995543A patent/NO327603B1/no not_active IP Right Cessation
- 1999-11-12 NO NO19995544A patent/NO316221B1/no not_active IP Right Cessation
-
2000
- 2000-06-29 HK HK00103938A patent/HK1024629A1/xx not_active IP Right Cessation
- 2000-08-14 HK HK00105042A patent/HK1025947A1/xx not_active IP Right Cessation
-
2002
- 2002-01-30 US US10/060,734 patent/US6617352B2/en not_active Expired - Fee Related
- 2002-04-02 US US10/114,351 patent/US7375252B2/en not_active Expired - Fee Related
- 2002-04-02 US US10/114,346 patent/US6602914B2/en not_active Expired - Fee Related
- 2002-04-02 US US10/115,206 patent/US6828447B2/en not_active Expired - Fee Related
-
2003
- 2003-05-19 NO NO20032254A patent/NO319855B1/no not_active IP Right Cessation
- 2003-08-25 US US10/647,766 patent/US7189870B2/en not_active Expired - Fee Related
-
2004
- 2004-10-14 IL IL164568A patent/IL164568A/en not_active IP Right Cessation
-
2006
- 2006-04-19 JP JP2006115258A patent/JP2006232848A/ja active Pending
- 2006-04-20 JP JP2006116322A patent/JP2006265257A/ja active Pending
- 2006-04-24 IL IL175130A patent/IL175130A/en not_active IP Right Cessation
- 2006-09-13 IL IL178072A patent/IL178072A/en not_active IP Right Cessation
- 2006-12-19 KR KR1020067026799A patent/KR100919883B1/ko not_active IP Right Cessation
-
2007
- 2007-06-04 CY CY20071100732T patent/CY1107645T1/el unknown
-
2008
- 2008-05-15 US US12/121,464 patent/US20080214660A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010090148A (ja) * | 2002-07-12 | 2010-04-22 | Atherogenics Inc | 低溶解性プロブコールエステル類およびエーテル類の新規な塩形態 |
JP2006516133A (ja) * | 2002-12-24 | 2006-06-22 | アースロン・リミテッド | Fc受容体調節化合物および組成物 |
JP2006516569A (ja) * | 2003-01-13 | 2006-07-06 | アセロジエニクス・インコーポレイテツド | プロブコールおよびその誘導体のエステルおよびエーテルの製造方法 |
JP2007512262A (ja) * | 2003-11-25 | 2007-05-17 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療のための新規な化合物 |
JP2007532538A (ja) * | 2004-04-09 | 2007-11-15 | キャンブレックス チャールズ シティ インコーポレイテッド | プロブコール誘導体の製造方法 |
JP2008505097A (ja) * | 2004-07-01 | 2008-02-21 | アセロジエニクス・インコーポレイテツド | 糖尿病性血管疾患を治療するための化合物および方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002503227A (ja) | Vcam−1発現を阻害する化合物および方法 | |
EP1464639B1 (en) | Succinic acid ester of probucol for the inhibition of the expression of VCAM-1 | |
CA2562992C (en) | Probucol analogues, and use thereof as anti-inflammatory inhibitors of vcam-1 | |
AU2006202461B2 (en) | Compositions and methods for the inhibition of the expression of VCAM-1 | |
AU2002300328B2 (en) | Compounds and methods for the inhibition of the expression of VCAM-1 | |
EP1726582A2 (en) | Compounds and methods for the inhibition of the expression of vcam-1 | |
EP1695959A1 (en) | Compouds and methods for the inhibition of the expression of VCAM-1 | |
MXPA99010402A (en) | Compounds and methods for the inhibition of the expression of vcam-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060420 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20060420 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20060619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060927 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061113 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070227 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070308 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110316 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120316 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130316 Year of fee payment: 6 |